STAT+: Eli Lilly and the ‘societal obligation’ of GLP-1s
Why it matters: Big Pharma is navigating drug accessibility and strategic acquisitions, shaping future health treatments.
- Eli Lilly is facing a "societal obligation" regarding its GLP-1 medications, a key discussion point in the biotech sector.
- Merck has announced the acquisition of Terns Pharma, indicating strategic growth and investment.
- Former Loxo executives are gaining prominence at Lilly, suggesting a shift in leadership and potentially strategic direction within the company, as noted by STAT News.
Eli Lilly is grappling with the "societal obligation" of its GLP-1 drugs, a topic highlighted in today's biotech news. Meanwhile, Merck is expanding its portfolio with the acquisition of Terns Pharma, signaling significant movement in the pharmaceutical landscape.
